We read with interest the report by Eckardt and Licht 1 in a recent issue of CHEST (December 2012). Although we congratulate them for their effort in clarifying the potential superiority of open pulmonary metastasectomy for treatment of patients with resectable pulmonary metastases, we want to share some signifi cant concerns.
Dilemma in Pulmonary Metastasectomy
Video-Assisted Thoracoscopic Surgery or Thoracotomy?
To the Editor:
We read with interest the report by Eckardt and Licht 1 in a recent issue of CHEST (December 2012). Although we congratulate them for their effort in clarifying the potential superiority of open pulmonary metastasectomy for treatment of patients with resectable pulmonary metastases, we want to share some signifi cant concerns.
Both preoperative imaging and procedure via video-assisted thoracoscopic surgery (VATS) might miss some small metastatic nodules. 2 The authors argued that the missed metastases might lead to higher recurrence rate and more mediastinal lymph node involvement, both of which might be detrimental to prognosis of those patients. However, VATS has been shown to be less invasive, with minor pain, trauma, and immune disturbance, and to better preserve quality of life and compliance with subsequent adjuvant therapy. 3 In addition, metastasis of malignance is a systematic disease. Some recurrent pulmonary metastases may come from another micrometastasis other than the possibly missed lesions. Also, whether the mediastinal lymph node involvement is due to the pulmonary metastases or other lymphatic micrometastasis is still controversial. 4 Moreover, a few retrospective case-control studies concluded that survival after metastasectomy by VATS was not inferior to open surgery. 4 Several studies also reported that repeated metastasectomy was performed in 10% to 20% of patients who had undergone metastasectomy for the fi rst time, and the survival curves were equal between the fi rst and the fi rst repeated metastasectomy (24.0% to 56.0% vs 23.0% to 53.8%). 4 With regard to this report, VATS should be technically comparable to open thoracotomy in resection of those 55 imaged nodules, even though some of them might not be palpable. Speculatively, we presumed that the four nonpalpable nodules via VATS were not metastatic lesions. Then the ratio of improper resection caused by VATS and thoracotomy was 18.2 (10 of 55) and 35% (28 of 80), respectively ( P , .05). Therefore, we have several concerns: (1) Can the total recurrence rate be actually reduced by the relatively radical resection the fi rst time? (2) Is it defi nitely benefi cial at the cost of more invasiveness and such a high rate of excessive treatment caused by open thoracotomy? (3) If resectable recurrent metastases do happen, what can we do for a patient who has undergone an open thoracotomy?
We argue that factors such as effi cacy, invasiveness, compliance, and preservation of quality of life should be all taken into consideration when planning a palliative treatment strategy such as pulmonary metastasectomy. We are also looking forward to more prospective randomized trials with more cases included to elucidate all confusions .
Chengwu Liu , MD Lunxu Liu , MD, PhD
Chengdu, China
Steroids and Arteriovenous Thrombosis
The Role of Underlying Disease
To the Editor:
Recently in CHEST (May 2013), Stuijver and colleagues 1 suggested that iatrogenic corticosteroids are risk factors for pulmonary embolism as much as endogenous steroids are associated with an increased risk of thrombosis. In this context, it is useful to note that thrombotic risk with corticosteroids not only is restricted to venous circulation but also involves the arterial side. A recent study by Fardet and colleagues 2 suggested that iatrogenic corticosteroids are risk factors for cardiovascular disease. This analysis, as in the present study, possibly refl ects the increased cardiovascular risk associated with the disease conditions for which steroids are prescribed. Subclinical atherosclerosis is noted in many conditions where chronic infl ammation is a pathophysiologic factor. 3 However, Fardet and colleagues 2 noted cardiovascular events with long-term use of corticosteroids but not venous thrombosis . In these cases, long-term suppression of the underlying infl ammatory state would have been necessary. In other words, steroid use in the initial period of the prescription and at higher doses is an additional risk factor for venous thrombosis, whereas smaller-dose, long-term prescriptions are risk factors for arterial thrombosis.
What does this signify? In both cases, the underlying disease condition matters as much as the steroid usage, but development of venous thrombosis also suggests high levels of infl ammation associated with the underlying disease, whereas arterial thrombosis denotes low-grade infl ammation and secondary atherosclerosis. In summary, the venous and arterial thrombotic risks associated with steroids most possibly refl ect the severity of the underlying diseases that required these drugs, with the contribution from these drugs itself being an additive effect.
Response

To the Editor:
Drs Liu and Liu raise a concern about open pulmonary metastasectomy in their letter regarding our recent article in CHEST (December 2012). 1 They argue that video-assisted thoracoscopic surgery (VATS) is preferable over thoracotomy because it is less invasive-an assumption which is shared by most thoracic surgeons even though the evidence base for this assumption is low. 2 Drs Liu and Liu raise an important question for which there is no answer in the existing literature, including our article: namely, whether recurrence rates after metastasectomy can be reduced by a more radical resection during thoracotomy compared with VATS. The authors argue that factors such as effi cacy, invasiveness, compliance, and preservation of quality of life should be taken into consideration when planning pulmonary metastasectomy, a belief which is spreading in the thoracic community 3 but which is also against current recommendations. 4 In our article, which is the fi rst, to our knowledge, observer-blinded study investigating VATS vs open metastasectomy, we demonstrated that even in the 21st century, in a high-volume VATS center that uses modern surgical technology, metastatic disease is not completely removed when manual palpation is restricted by the port holes. Whether survival rates or recurrence rates are different between thoracotomy and (repeated) VATS procedures is currently unknown, and we certainly agree with Drs Liu and Liu that more prospective trials are needed. We urge the thoracic surgical community to launch large prospective randomized multicenter trials on this topic .
